Press releases

Stockholm – 26 April 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Annual Report for 2018 now is available at the company’s website, www.oncopeptides.com and can be found under Investors & media / Financial reports

Stockholm – 24 April 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the company will provide an update on patient recruitment in the ongoing phase 3 study OCEAN, as well as a general update from all the company's clinical studies in a webcast at 10.00am (CET) today

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden, Tuesday 21 May 2019 at 2.00 p.m. Coffee will be served starting at 1.00 p.m., at which time the registration for attendees will commence

Stockholm - April 11, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has updated its financial calendar, the interim report for Q2 2019 have been moved to 28 August. The dates for future reports and the AGM are shown below. Oncopeptides will also host a webcast on the same day as the interim reports are published

Stockholm - 10 April 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the US patent and trademark office has issued a notice that they intend to grant additional patents to Oncopeptides AB in the US. Oncopeptides has previously received the corresponding patent protection both in Japan and Europe

Stockholm — 27 February 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that data from its Phase II HORIZON study and Phase I/II ANCHOR study evaluating the company’s novel candidate melflufen, a peptide-conjugated alkylator belonging to the novel class of peptidase enhanced

Stockholm – February 25, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Jakob Lindberg, CEO at Oncopeptides, will present the company at Cowen and Company 39th Annual Healthcare Conference in Boston on March 11th at 4:10 pm Eastern Standard Time, the presentation will be webcasted

Summary of Q4 Financial overview October 1 – December 31, 2018 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 111.4 M (loss: 66.2) Loss per share, before and after dilution, was 2.53 (loss: 1.68) SEK On December 31 cash and cash equivalents amounted to SEK 375.6 M (404.1)

Stockholm —18 February 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Company will release its Year-end Report on 22 February at 8:00 am CET. The report will be available on the Company’s web site at www.oncopeptides.com

Stockholm —31 January, 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 4,750,000 shares, which was carried out in January 2019